RxDoctor Payments Data

Katina Matthews Ferrari, MD

Psychiatry · Punta Gorda, FLNPI 1124038013

Payments from drug & device makers

$5,029in general payments, 2019–2025

Across 101 payments — averaging $49.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$3K
  • Sunovion Pharmaceuticals Inc.$327
  • AbbVie$303
  • Alkermes, Inc.$254
  • Teva Pharmaceuticals USA, Inc.$227
  • Neurocrine Biosciences, Inc.$198
  • plus $1K from 15 others

What the payments were for

  • Speaking & faculty fees$2,46449%
  • Food & beverage$2,49950%
  • Education$661%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,029 in reported general payments places this provider in the 80th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$18,571
Medicare patients
124
Services billed
253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate22$183,865
IngrezzaValbenazine Tosylate12$101,435
CaplytaLumateperone Tosylate33$54,332
VraylarCariprazine Hcl22$34,158
Risperdal ConstaRisperidone Microspheres22$26,604
RexultiBrexpiprazole13$19,005
Paliperidone ErPaliperidone70$17,610
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl127$17,373
Aripiprazole147$16,966
VyvanseLisdexamfetamine Dimesylate23$8,702
Clozapine100$8,497
ZubsolvBuprenorphine Hcl/Naloxone Hcl17$6,631
Quetiapine Fumarate ErQuetiapine Fumarate52$4,604
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine67$3,896
Oxcarbazepine57$3,867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$198$101,43512 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$175$54,33233 claims
AbbVieVraylar$303$34,15822 claims
Otsuka America Pharmaceutical, Inc.Rexulti$2,682$19,00513 claims
Orexo US, Inc.Zubsolv$16$6,63117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Punta Gorda

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →